Retinoblastoma regression following intra-arterial chemotherapy to the contralateral eye
Open Access
- 1 July 2019
- journal article
- research article
- Published by Medknow in Saudi Journal of Ophthalmology
- Vol. 33 (3) , 291-293
Abstract
Intra-arterial chemotherapy (IAC) has assumed a major role in the management of retinoblastoma. This targeted therapy involves the delivery of chemotherapy directly into the ophthalmic artery, minimizing systemic absorption. We report a case of retinoblastoma regression in the untreated eye following IAC to the contralateral eye.Keywords
This publication has 7 references indexed in Scilit:
- Primary Intra-Arterial Chemotherapy for Retinoblastoma in the Intravitreal Chemotherapy Era: Five Years of ExperienceOcular Oncology and Pathology, 2018
- Intra-arterial Chemotherapy for Retinoblastoma in 70 EyesOphthalmology, 2014
- Clinical Pharmacokinetics of Intra-arterial Melphalan and Topotecan Combination in Patients with RetinoblastomaOphthalmology, 2014
- Retinoblastoma frontiers with intravenous, intra-arterial, periocular, and intravitreal chemotherapyEye, 2012
- Intra-arterial Chemotherapy for the Management of RetinoblastomaArchives of Ophthalmology (1950), 2011
- Effects on the Contralateral Eye After Intravitreal Bevacizumab and Ranibizumab Injections: A Case ReportAnnals of the Academy of Medicine, Singapore, 2008
- Effects on the contralateral eye after intravitreal bevacizumab and ranibizumab injections: a case report.2008